Drug development for urgent medical needs
About
IHP Therapeutics is developing IHP-009, a Phase 3 ready new molecule to treat patients hospitalized with COVID-19. Our pipeline programs include novel carbohydrate-based drugs to treat inflammation and the pathologies of infectious diseases.
Mission
To improve and save lives through scientific discovery and development of therapeutics.
Our Team
Rinko Ghosh, MS, MBA
CEO
Gabriel Njikang, PhD
Director of CMC Project Management
​
Jocelyn Jackson
Acting CFO
John Paderi, PhD
Chief Science Officer
​
Sami Karaborni, PhD
Head of CMC
Kate Stuart, PhD
VP of Program Management
​
Peggy McLaughlin
VP of Clinical Operations
Robert Van Gorp
Chief Operations Officer
Board of Directors
Rinko Ghosh, MS, MBA
​
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
​
​
Clinical and Scientific Advisors
Science
IHP Therapeutics is building on nearly a century of clinical and basic science research with heparin and related carbohydrate-based compounds. While most widely recognized as an anticoagulant, heparin has numerous activities and heparin-derived compounds hold great promise for treating many different conditions, including infection and inflammation, which are critical for COVID-19. We are developing both novel compounds as well as late clinical-stage drugs like IHP-009, a new chemical entity with an established clinical safety profile. Our goal is to translate the therapeutic potential of these carbohydrate-based compounds into clinically significant benefits for patients.
Pipeline
